bluebird bio is a biotechnology company that focuses on pioneering gene therapies to treat severe genetic diseases and cancer. The company operates in the healthcare and biotechnology market, targeting conditions that currently have limited or no treatment options. Their primary clients include patients suffering from cerebral adrenoleukodystrophy, multiple myeloma, sickle cell disease, and transfusion-dependent beta-thalassemia. These are serious conditions that can significantly impact a person's quality of life and longevity.

The business model of bluebird bio revolves around developing and commercializing gene therapies. Gene therapy is a cutting-edge technique that involves altering the genes inside a patient's cells to treat or prevent disease. The company uses various advanced techniques such as gene addition therapy, cancer immunotherapy, and gene editing to create these treatments. They are involved in all stages of the development process, from initial research and clinical trials to regulatory approval and commercialization.

bluebird bio makes money by bringing these innovative therapies to market. Once a therapy is approved by regulatory bodies, the company can sell it to healthcare providers and patients. They also engage in collaborations and partnerships with other organizations in the biotech and pharmaceutical industries, which can provide additional revenue streams through licensing agreements and shared research initiatives.

In summary, bluebird bio is at the forefront of medical innovation, aiming to rewrite the stories of patients with severe genetic diseases and cancer through groundbreaking gene therapies.

Keywords: gene therapy, biotechnology, genetic diseases, cancer, healthcare, innovation, clinical trials, gene editing, immunotherapy, medical treatments.